Coherus BioSciences has sold its Humira biosimilar, Yusimry, to Hong Kong-based King-Friend Industrial for $40 million in cash. This marks the second divestiture of a biosimilar this year by Coherus, based in Redwood City.
Coherus BioSciences announced it agreed to sell its Humira biosimilar Yusimry to Hong Kong-based King-Friend Industrial for $40M in cash. Which biosimilars are covered by the top 3 prescription drug insurance /PBM formularies? Hyrimoz is jointly marketed by CVS-owned Cordavis https://t.co/zaZyAQS3Ha
The move represents the second divestiture of a biosimilar this year by Redwood City-based Coherus. https://t.co/J6U31RXh5B
Coherus divests 'biosimilar' of Humira for $40 million upfront $CHRS https://t.co/LNl58Fem96 via @SFBusinessTimes
Humira biosimilar sold for just $40M... https://t.co/Np3Ywu5jE1
What's a Humira biosimilar worth? Apparently only $40 million: https://t.co/VtKCNxiwcg